Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01683994 · ClinicalTrials.gov registry record · Phase 1
Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
NCT01683994: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT01683994 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 49 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01683994, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
Study Summary
Background: \- Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate tumors respond to it. Docetaxel and prednisone are standard treatments for advanced prostate cancer. Researchers want to see if adding cabozantinib to these two drugs can be a safe and effective treatment for this type of cancer. Objectives: \- To test the safety and effectiveness of cabozantinib with standard treatments for advanced prostate cancer. Eligibility: \- Individuals at least 18 years of age who have advanced prostate cancer that has not responded to standard treatments. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. Imaging studies will also be performed. * Participants will receive the cancer drugs over 21-day cycles of treatment. They will take docetaxel and cabozantinib on day 1 of each cycle. Each docetaxel infusion will take about 1 hour. They will also take prednisone by mouth twice each day. * Treatment will be monitored with frequent blood tests and imaging studies. * Participants will continue to take the study drugs for as long as their cancer does not worsen and side effects are not too severe.
Interventions
- DRUG Docetaxel
- DRUG Prednisone
- DRUG Cabozantinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-09-07 |
| Est. Completion | 2019-01-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01683994
The ClinicalTrials.gov registry entry for NCT01683994 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01683994 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01683994 about?
NCT01683994 is a clinical study titled "Cabozantinib Plus Docetaxel and Prednisone for Advanced Prostate Cancer". Background: \- Cabozantinib is a drug that slows the growth of blood vessels that feed tumors. It is approved for medullary thyroid cancer. However, studies have shown that prostate tumors respond to it. Docetaxel and prednisone are standard treatments for advanced prostate cancer. Researchers want...
What is the current status of trial NCT01683994?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2012-09-07. Estimated completion is 2019-01-16.
What interventions are being tested in trial NCT01683994?
The interventions under investigation include: Docetaxel (DRUG), Prednisone (DRUG), Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT01683994?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.